Call Now Open
2026 Oxford-Harrington Rare Disease Scholar Award
Medicines in the making
Institutions supported
Companies launched
Medicines in the clinic
Licenses to pharma
In addition to receiving funding, every scholar is paired with a results-oriented and mission-focused team from our Therapeutics Development Center. Teams consist of a project manager and experienced pharma and business development advisors with a track record of bringing new drugs to market.
Learn MoreOur pipeline represents the best science coming out of academic laboratories. Projects are selected for their innovation and potential for clinical impact. Our team proactively moves them forward to commercial viability and clinical use.
See All DiscoveriesBy concentrating philanthropic, scientific, and business development resources during the high-risk stages of drug development, Harrington ‘de-risks’ therapeutic candidates and positions them for further investment and commercialization.
Learn More
Prestigious Scholar Award Accelerates Novel Therapies for Patients with Rare Diseases
Continue Reading
This interactive, informational webinar will outline the award’s key eligibility requirements and highlight the elements of a competitive proposal. Attendees will have the opportunity to ask questions.
Register
Harrington Discovery Institute at University Hospitals is supporting the development of a new drug called Zalunfiban that helped thousands of heart attack patients avoid complications in clinical trials.
Continue Reading
Oxford-Harrington Rare Disease Centre operates a transatlantic model that embeds industry expertise directly into academic rare disease programs. $250 Million Committed to Advance 40 Therapies into Clinical Trials by 2034
Continue Reading